46.49 +0.12 (0.26%)
After hours: 5:35PM EDT
|Bid||46.05 x 800|
|Ask||46.47 x 900|
|Day's Range||44.73 - 47.38|
|52 Week Range||16.16 - 73.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||66.93|
ZUG, Switzerland and CAMBRIDGE, Mass., Sept. 20, 2018-- CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced ...
Dow Jones futures: Tilray and other marijuana stocks were active Thursday after a wild Wednesday. Red Hat fell on weak sales and guidance. Crispr slid on a stock offering.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that struck 52-week highs on Sept. 19.) Acceleron Pharma Inc (NASDAQ: XLRN ...
Tilray TLRY stock fell as much as 16 percent in after-hours trading, following a volatile trading day for the Canadian cannabis company. Shares closed up 38 percent, its best day ever as a public company, after surging as much as 90 percent during the day. The company also posted a strong run on Tuesday after the U.S. Drug Enforcement Administration gave the company the green light to import marijuana to the U.S. for medical research.
Shares of Crispr Therapeutics AG fell 5% in the extended session Wednesday after the gene-editing company said it plans to offer $200 million worth of shares of its common stock in a public offering. Underwriters will be granted a 30-day option to buy an additional $30 million, the company said in a statement. Goldman Sachs and Piper Jaffray are joint book-runners. Shares of Crispr ended the regular trading session down 2.4%.
CRISPR Therapeutics (CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that it is commencing an underwritten public offering of $200,000,000 of its common shares. In addition, the underwriters will have a 30-day option to purchase up to $30,000,000 of additional common shares at the public offering price less the underwriting discount. Goldman Sachs & Co. LLC, Piper Jaffray & Co., Barclays Capital Inc. and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering.
HENDERSON, NV / ACCESSWIRE / September 19, 2018 / The stem cell market has been very active recently, several stocks have been making deals and major breakthroughs. One stem cell play the market seems ...
-Aims to develop an immune-evasive stem cell therapy as a potentially curative treatment for diabetes-. -Parties will collaborate through commercialization and share costs and profits worldwide-. ZUG, ...
Crispr Therapeutics (CRSP) has risen 130.62% YTD (year-to-date). This leading gene-editing company is focused on leveraging the CRISPR-Cas9 technology for developing therapies that target multiple hematology, immune-oncology, liver, and other organ-related indications.
In the second quarter, Intellia Therapeutics (NTLA) reported collaboration revenue of $7.7 million compared to $5.9 million in the second quarter of 2017. Intellia Therapeutics’ collaboration agreement with Regeneron Pharmaceuticals (REGN) primarily contributed to the increase in its collaboration revenue in the second quarter. In the first half of 2018, Intellia Therapeutics reported net collaboration revenue of $15.1 million compared to $12.1 million in the first half of 2017.
Intellia Therapeutics is a genome-editing company that’s currently focused on the development of curative therapies utilizing the CRISPR/Cas9 system. In August, Intellia Therapeutics presented data from a study in which a humanized mouse model of hereditary transthyretin amyloidosis demonstrated a reduction in amyloid deposition in multiple tissues after the administration of a single dose of lipid nanoparticles. Of the seven analysts tracking Intellia Therapeutics in September, three have recommended “strong buys,” while three have recommended “buys” on its stock.
In the second quarter, Editas Medicine (EDIT) reported revenues of $7.3 million from collaborations and other R&D (research and development) activities. In comparison, the company’s revenues reached $3.1 million in the second quarter of 2017.
The interference proceeding remains terminated without any determination on inventorship of CRISPR/Cas9 genome editing application to eukaryotic cells University of California/University of Vienna/Dr. ...
The U.S. Court of Appeals for the Federal Circuit affirmed the validity of the Harvard and MIT patents, rejecting a challenge brought by a rival team of researchers associated with the University of California at Berkeley and University of Vienna in Austria. Shares of Cambridge, Massachusetts-based Editas Medicine Inc, a biotechnology company that licenses Harvard and MIT's CRISPR-related patents, rose nearly 7 percent after the ruling before giving back most of those gains and was up 1 percent at $30.56.
In the second quarter, CRISPR Therapeutics reported net income and EPS (earnings per share) of -$38.4 million and -$0.82, respectively, compared to net income and EPS of -$22.3 million and -$0.56 in the second quarter of 2017. In the first half of the year, CRISPR Therapeutics reported net income and EPS of -$66.7 million and -$1.44, respectively, compared to -$43.8 million and -$1.10 in the first half of 2017.
CRISPR Therapeutics (CRSP) has already obtained approval for clinical trial applications (or CTA) across multiple countries for its CTX001, an investigational autologous gene-edited hematopoietic stem cell therapy for the treatment of individuals with severe hemoglobinopathies. CRISPR Therapeutics and its partner, Vertex Pharmaceuticals, obtained CTA approvals for the evaluation of the therapy for the treatment of beta-thalassemia and sickle cell disease.
CRISPR Therapeutics might lead its start-up peers, but its collaboration partner is the better stock to buy.
The three leading CRISPR gene-editing companies announced first-half 2018 earnings last month, and received a boost on the final day of August.
NEW YORK, NY / ACCESSWIRE / September 4, 2018 / Major U.S. equities closed mostly higher on Friday and posted upbeat performance for the week. Market volatility source have been coming from U.S. and international ...
The allure of mega-returns can make penny stocks attractive. The reality is, this isn't where you'll find the next Apple or Amazon, and there is far more risk than potential reward. Here are three far better risk-reward investments to consider.
CRISPR gene editing has endured a rough 2018 after years of hype. One start-up, which shares founders and tech with Editas Medicine, thinks it can move the field forward.